Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Phase 1 / Phase 2 | suspended | Aug 1, 2019 | Clovis Oncology, Inc. | Company decision | Sponsor / business decision |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based… | Phase 1 / Phase 2 | terminated | Apr 20, 2021 | Xennials Therapeutics Australia Pty Ltd | Study was terminated by IP Holder (collaborator), PinotBio Inc. | Other (stated, no rule matched) |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT03971110 | A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer… | Phase 4 | terminated | Jun 3, 2019 | AstraZeneca | Due to the limited potential patients pool, the enrollment goal could not be achieved. After review… | Enrollment / accrual |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With… | Phase 2 | terminated | Nov 30, 2016 | Marker Therapeutics, Inc. | Futility analysis did not support continuation of the trial | Efficacy / futility |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | — | withdrawn | Sep 30, 2021 | Indiana University | PI decision to cancel research | Other (stated, no rule matched) |
| NCT04742972 | Prostate PMSABR Study | N/A | withdrawn | Feb 8, 2021 | Darren Poon | The lack of well-defined oligometastasis, high disease burden in mCRPC and high sensitivity of… | Enrollment / accrual |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | Phase 1 | terminated | Dec 17, 2020 | Rubius Therapeutics | The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | Phase 2 | withdrawn | Mar 4, 2020 | Instituto Nacional de Cancerologia, Columbia | Issues with local regulatory authority | Other (stated, no rule matched) |
| NCT03801031 | Sexual Dysfunction in Gynecologic Oncology Patients | Phase 4 | terminated | Jan 11, 2019 | David Bender | Slow accrual | Enrollment / accrual |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT02933073 | Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma | Phase 1 | terminated | Oct 14, 2016 | UConn Health | Study recruitment is temporary on hold by the sponsor due to patient recruitment challenges and the… | Enrollment / accrual |
| NCT04928820 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer… | Phase 2 | terminated | Jun 16, 2021 | Jonsson Comprehensive Cancer Center | slow recruitment | Enrollment / accrual |
| NCT00581503 | Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and… | — | withdrawn | Dec 27, 2007 | University of California, Irvine | Not NIH defined clinical trial | Other (stated, no rule matched) |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | N/A | withdrawn | Apr 29, 2020 | Dana-Farber Cancer Institute | The anomaly detection system is still under development and is not ready to test. | Other (stated, no rule matched) |
| NCT04727710 | Testing the Effect of Mindfulness for Prostatectomy Outcomes(TEMPO) | N/A | terminated | Jan 27, 2021 | University of Michigan Rogel Cancer Center | Study was held due to COVID19 and unable to enroll in virtual platform | COVID-19 / pandemic |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon…(ESCALATE) | Phase 3 | terminated | Jan 23, 2020 | MANA RBM | The study was stopped due to insurmountable enrollment challenges affecting trial accrual,… | Enrollment / accrual |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant… | Phase 1 / Phase 2 | withdrawn | Oct 17, 2018 | Roswell Park Cancer Institute | lack of funding | Funding |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical… | Phase 3 | withdrawn | Jun 29, 2021 | Agenus Inc. | Strategic Business Decision | Sponsor / business decision |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | Phase 1 | terminated | Aug 3, 2010 | Roswell Park Cancer Institute | no value in finding efficacy | Efficacy / futility |
| NCT04535908 | Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older. | N/A | terminated | Sep 2, 2020 | Medical University of Graz | Treatment standard has changed. | Other (stated, no rule matched) |
| NCT02766478 | Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing…(GeniPro) | Phase 2 | terminated | May 9, 2016 | Emory University | Enrollment and study activities were suspended due to COVID-19. | COVID-19 / pandemic |
| NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing… | Phase 2 | terminated | Sep 7, 2006 | Craig L Slingluff, Jr | Slow enrollment rate. | Enrollment / accrual |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in… | Phase 1 | terminated | Feb 21, 2020 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation… | Phase 2 | terminated | Jul 30, 2014 | National Cancer Institute (NCI) | Eli Lilly prematurely terminated the study. | Other (stated, no rule matched) |
| NCT02290366 | Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk… | N/A | withdrawn | Nov 14, 2014 | Ronald M. Benoit, MD | Principal Investigator decision | Investigator |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23,… | Phase 1 | terminated | Sep 24, 2020 | Shanghai East Hospital | Both the sponsors and collaborator are considering terminating the study. | Other (stated, no rule matched) |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | Phase 1 / Phase 2 | withdrawn | Jan 13, 2022 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian… | Phase 1 | withdrawn | Apr 21, 2014 | Rutgers, The State University of New Jersey | Research cancelled | Other (stated, no rule matched) |
| NCT02419846 | Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly… | N/A | terminated | Apr 17, 2015 | Case Comprehensive Cancer Center | Unable to recruit due to COVID limitations / Funding Unavailable | COVID-19 / pandemic |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With… | Phase 2 | terminated | May 22, 2018 | National Cancer Institute (NCI) | Study was closed for toxicity. | Safety / toxicity |
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen… | Phase 2 | terminated | Sep 10, 2012 | Costantine Albany | lack of accrual | Enrollment / accrual |
| NCT02582749 | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With… | Phase 2 | terminated | Oct 21, 2015 | Ajjai Alva, MD | Funding withdrawn | Funding |
| NCT04288336 | Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients… | Early Phase 1 | withdrawn | Feb 28, 2020 | Mayo Clinic | No patient accrual | Enrollment / accrual |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With… | Phase 1 | terminated | Nov 18, 2020 | Dizal Pharmaceuticals | Due to reasons of internal business strategy, not related to study or site conduct. | Sponsor / business decision |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT02663908 | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With…(PRONOUNCE) | Phase 3 | terminated | Jan 26, 2016 | Ferring Pharmaceuticals | Recruitment rate; a lower than anticipated observed cardiovascular event rate. The Sponsor decision… | COVID-19 / pandemic |
| NCT03964337 | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk…(SPARC) | Phase 2 | terminated | May 28, 2019 | Duke University | Poor accrual. | Enrollment / accrual |
| NCT03827993 | Improving Sexual Health in Gynecologic Cancer Patients | N/A | terminated | Feb 4, 2019 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT04941378 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian… | Phase 1 | withdrawn | Jun 28, 2021 | Abramson Cancer Center at Penn Medicine | Due to sponsor request | Other (stated, no rule matched) |
| NCT03290508 | Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate… | — | terminated | Sep 25, 2017 | Myriad Genetic Laboratories, Inc. | There is sufficient follow-up data to meet the endpoints of the study. | Other (stated, no rule matched) |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | Phase 2 | terminated | Jul 19, 2016 | University of Alabama at Birmingham | Poor accrual | Enrollment / accrual |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT02365883 | Transrectal Photoacoustic Imaging of the Prostate | — | terminated | Feb 19, 2015 | Stanford University | PI passed away | Other (stated, no rule matched) |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing… | Early Phase 1 | terminated | Dec 26, 2017 | National Cancer Institute (NCI) | it was decided that due to lack of accrual on the trial, and low potential for accruing over the… | Enrollment / accrual |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian,…(ORION-01) | Phase 1 / Phase 2 | terminated | Apr 4, 2017 | National Cancer Centre, Singapore | The study had poor efficacy. | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Dec 20, 2022source: clinicaltrials